Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT05534646Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in castration-resistant prostate cancer (CRPC). Started Dec 2023; status: recruiting.
02
Drugs
carotuximab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05534646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534646.